Can immunotherapy be safely used in early lung cancer? a Real-World study investigates

NCT ID NCT07760519

Not yet recruiting Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This observational study follows Indian adults with resectable non-small cell lung cancer who are prescribed durvalumab as part of their routine care. The goal is to monitor how often patients experience serious side effects, including severe adverse events and other complications. By reviewing medical records, researchers aim to better understand the real-world safety of this immunotherapy in this specific population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (IMFINZI), an immunotherapy drug
What this could lead to: If this study shows durvalumab is safe in this population, it could support its wider use as a standard treatment for early-stage lung cancer in India.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove effectiveness. It only tracks safety in a small group, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

More trials for these conditions

Other studies related to the condition(s) this trial covers.